Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million
individuals and is responsible for over 1.7 million deaths to date. Infection is associated with the …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory
syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and …

More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding
domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell
responses that continue to evolve for at least a year. During that time, memory B cells express …

The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals
1 , 2 – 3 . Despite the reduced protection from infection, individuals who received three …

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Feedback inhibition of humoral immunity by antibodies was first documented in 1909 1 .
Subsequent studies showed that, depending on the context, antibodies can enhance or inhibit …